137 related articles for article (PubMed ID: 8695826)
21. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
Bow EJ; Sutherland JA; Kilpatrick MG; Williams GJ; Clinch JJ; Shore TB; Rubinger M; Schacter BA
J Clin Oncol; 1996 Apr; 14(4):1345-52. PubMed ID: 8648393
[TBL] [Abstract][Full Text] [Related]
22. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
[TBL] [Abstract][Full Text] [Related]
23. Intensifying induction therapy in acute myeloid leukemia by an infusional chemotherapy schedule.
Friedenberg WR
Cancer Invest; 1998; 16(7):542-3. PubMed ID: 9774962
[No Abstract] [Full Text] [Related]
24. [Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period].
Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Pivnik AV; Khoroshko ND; Ol'shanskaia IuV; Tikhonova LIu; Maslova ER; Kulikov SM
Ter Arkh; 1999; 71(7):13-20. PubMed ID: 10481861
[TBL] [Abstract][Full Text] [Related]
25. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
[TBL] [Abstract][Full Text] [Related]
26. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
27. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T; Miyawaki S; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Ohmoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Matsuoka A; Tomonaga M; Ohno R
J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
[TBL] [Abstract][Full Text] [Related]
28. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
Robles C; Kim KM; Oken MM; Bennett JM; Letendre L; Wiernik PH; O'Connell MJ; Cassileth PA
Leukemia; 2000 Aug; 14(8):1349-53. PubMed ID: 10942228
[TBL] [Abstract][Full Text] [Related]
29. Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
Russo D; Candoni A; Grattoni R; Bertone A; Zaja F
Haematologica; 1998 Mar; 83(3):281-2. PubMed ID: 9573683
[TBL] [Abstract][Full Text] [Related]
30. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
[TBL] [Abstract][Full Text] [Related]
31. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.
Thomas MB; Koller C; Yang Y; Shen Y; O'Brien S; Kantarjian H; Davis J; Estey E
Leukemia; 2003 May; 17(5):990-3. PubMed ID: 12750721
[No Abstract] [Full Text] [Related]
32. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
33. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.
Matthews JP; Bishop JF; Young GA; Juneja SK; Lowenthal RM; Garson OM; Cobcroft RG; Dodds AJ; Enno A; Gillett EA; Hermann RP; Joshua DE; Ma DD; Szer J; Taylor KM; Wolf M; Bradstock KF;
Br J Haematol; 2001 Jun; 113(3):727-36. PubMed ID: 11380464
[TBL] [Abstract][Full Text] [Related]
34. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
Iwakiri R; Ohta M; Mikoshiba M; Tsutsumi H; Kumakawa T; Mori M
Int J Hematol; 2002 Jan; 75(1):45-50. PubMed ID: 11843290
[TBL] [Abstract][Full Text] [Related]
36. [The results of a multicenter cooperative study on treating acute myeloid leukemias in adults].
Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Kulikov SM; Tikhonova LIu; Cherepanova VV; Rekhtman GB; Medvedeva NV; Kaporskaia TS
Ter Arkh; 1994; 66(7):11-7. PubMed ID: 7985120
[No Abstract] [Full Text] [Related]
37. SAB--a promising new treatment to improve remission rates in AML in the elderly?
Wheatley K
Br J Haematol; 2002 Aug; 118(2):432-3. PubMed ID: 12139727
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte macrophage--colony stimulating factor (GM-CSF) as adjunct in induction therapy of acute myeloid leukemia.
Gangadharan VP; Prakash NP; Jayasree K; Nayak N
Indian J Cancer; 1999 Mar; 36(1):32-7. PubMed ID: 10810552
[TBL] [Abstract][Full Text] [Related]
39. Control of acute myeloid leukemia morbidity in northwest Iran.
Eivazi-Ziaei J
Asian Pac J Cancer Prev; 2005; 6(4):472-3. PubMed ID: 16435994
[TBL] [Abstract][Full Text] [Related]
40. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Sonneveld P; Burnett A; Vossebeld P; Ben-Am M; Rosenkranz G; Pfister C; Verhoef G; Dekker A; Ossenkoppele G; Ferrant C; Yin L; Gratwohl A; Kovacsovics T; Vellenga E; Capdeville R; Löwenberg B
Hematol J; 2000; 1(6):411-21. PubMed ID: 11920222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
